The most common adverse effects are headache, which occurs in 4â€“11% of patients, and constipation in up to 6% of patients. In less than 1% of patients, other [[gastrointestinal disorder]]s occur, as well as [[sleeplessness]], [[First-degree atrioventricular block|first-]] and [[second-degree atrioventricular block]], [[myalgia|muscle pain]] and [[dyspnoea|shortness of breath]]. Palonosetron is similarly well tolerated as other setrons, and slightly less than [[placebo]].<ref name="AC" /><ref name="Dinnendahl" />

 

